CTAD 2026

van Dyck et al

 

Long-Term Outcomes with Lecanemab in Early Alzheimer's Disease: Initial Findings Through 60-Months of Clarity AD Open-Label Extension

Copies of these presentations obtained through the QR code are for personal use only and may not be used without permission from CTAD and the authors of this presentation.